Correction: Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera

Keita Kirito¹, Yuka Sugimoto², Akihiko Gotoh³, Katsuto Takenaka⁴, Michiko Ichii⁵, Tadaaki Inano^{6

7}, Shuichi Shirane^{6

7}, Masafumi Ito⁸, Oleh Zagrijtschuk⁹, Albert Qin¹⁰, Hiroaki Kawase¹¹, Toshiaki Sato¹¹, Norio Komatsu^{6

7

11}, Kazuya Shimoda¹²

Affiliations

¹ Department of Hematology and Oncology, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan. kirito@yamanashi.ac.jp.
² Department of Hematology and Oncology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
³ Department of Hematology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
⁴ Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, 454 Shitsukawa, Toon, Ehime, 791-0295, Japan.
⁵ Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
⁶ Department of Hematology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
⁷ Department of Advanced Hematology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
⁸ Department of Pathology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, 3-35 Michishita-cho, Nakamura-ku, Nagoya, Aichi, 453-8511, Japan.
⁹ PharmaEssentia Corporation USA, 35 Corporate Drive, Suite 325, Burlington, MA, 01803, USA.
¹⁰ Medical Research and Clinical Operations, PharmaEssentia Corporation, 13F, No. 3, YuanQu Street, Nangang District, Taipei, 115, Taiwan.
¹¹ PharmaEssentia Japan KK, Akasaka Center Building 12F, 1-3-13 Moto-akasaka, Minato-ku, Tokyo, 107-0051, Japan.
¹² Division of Hematology, Diabetes and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kiyotakecho Kihara, Miyazaki, Miyazaki, 889-1692, Japan.

PMID: 40377864
PMCID: PMC12202615
DOI: 10.1007/s12185-025-04002-3

Published Erratum

Correction: Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera

Keita Kirito et al. Int J Hematol. 2025 Jul.

. 2025 Jul;122(1):159-161.

doi: 10.1007/s12185-025-04002-3.

Authors

Affiliations

¹ Department of Hematology and Oncology, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan. kirito@yamanashi.ac.jp.
² Department of Hematology and Oncology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
³ Department of Hematology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
⁴ Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, 454 Shitsukawa, Toon, Ehime, 791-0295, Japan.
⁵ Department of Hematology and Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
⁶ Department of Hematology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
⁷ Department of Advanced Hematology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
⁸ Department of Pathology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, 3-35 Michishita-cho, Nakamura-ku, Nagoya, Aichi, 453-8511, Japan.
⁹ PharmaEssentia Corporation USA, 35 Corporate Drive, Suite 325, Burlington, MA, 01803, USA.
¹⁰ Medical Research and Clinical Operations, PharmaEssentia Corporation, 13F, No. 3, YuanQu Street, Nangang District, Taipei, 115, Taiwan.
¹¹ PharmaEssentia Japan KK, Akasaka Center Building 12F, 1-3-13 Moto-akasaka, Minato-ku, Tokyo, 107-0051, Japan.
¹² Division of Hematology, Diabetes and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kiyotakecho Kihara, Miyazaki, Miyazaki, 889-1692, Japan.

PMID: 40377864
PMCID: PMC12202615
DOI: 10.1007/s12185-025-04002-3

No abstract available

PubMed Disclaimer

Erratum for

Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera.
Kirito K, Sugimoto Y, Gotoh A, Takenaka K, Ichii M, Inano T, Shirane S, Ito M, Zagrijtschuk O, Qin A, Kawase H, Sato T, Komatsu N, Shimoda K. Kirito K, et al. Int J Hematol. 2024 Dec;120(6):675-683. doi: 10.1007/s12185-024-03846-5. Epub 2024 Oct 3. Int J Hematol. 2024. PMID: 39361233 Free PMC article. Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- PubMed Central
- Springer

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Correction: Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera

Affiliations

Correction: Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources